Bioventus OA Pain Business Returns to Growth Ahead of Schedule

Bioventus reported 3Q23 orthopedic sales of $110.1 million, +2.5% compared to the third quarter of 2022. For the first nine months of the year, the company generated $335.1 million in orthopedic sales, -0.1% compared to the prior year.

Double-digit volume gains for DUROLANE helped offset ongoing average selling price declines for both...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0